Table 2.
Characteristics of Syrian patients with diabetes and hypertension, Shatila primary care clinic, Beirut, Lebanon, 2013–2017
| Characteristics at first visit | DM-1 Only (n = 204) | DM-2 Only (n = 780) | HTN Only (n = 780) | DM + HTN (n = 880) | All patients (N = 2644) |
|---|---|---|---|---|---|
| Age - year (median, IQR) | 22 (12–32) | 51 (44–58) | 54 (47–62) | 57 (51–63) | 53 (45–61) |
| Age categories - year - n (%) | |||||
| <18 y | 75 (36) | 1 (< 1) | 2 (< 1) | 0 (0) | 78 (3) |
| > = 18- < 40 y | 112 (55) | 113 (14) | 79 (10) | 36 (4) | 340 (13) |
| > = 40- < 60y | 16 (8) | 506 (65) | 454 (58) | 513 (58) | 1489 (56) |
| > = 60 y | 1 (< 1) | 160 (20) | 245 (31) | 331 (38) | 737 (28) |
| Gender - n (%) | |||||
| Female | 88 (43) | 459 (59) | 534 (68) | 585 (66) | 1666 (63) |
| Male | 116 (57) | 321 (41) | 246 (32) | 295 (34) | 978 (37) |
| Place of residency - n (%) | |||||
| In catchment area | 55 (28) | 218 (29) | 271 (36) | 221 (26) | 765 (30) |
| Outside catchment area | 143 (72) | 539 (71) | 484 (64) | 623 (74) | 1789 (70) |
| Previously diagnosed - n (%) | |||||
| Yes | 199 (98) | 733 (94) | 760 (97) | 874 (99) | 2566 (97) |
| No - newly diagnosed | 5 (2) | 47 (6) | 20 (3) | 6 (<1) | 78 (3) |
| Cardiovascular co-morbiditya | |||||
| Yes | 2 (< 1) | 75 (10) | 158 (20) | 140 (16) | 375 (14) |
| No | 202 (99) | 705 (90) | 622 (80) | 740 (84) | 2269 (86) |
| HbA1C - % [mean (SD)] | 9.9 (2.1) | 8.9 (2.1) | NA | 8.7 (2.0) | 9.0 (2.1) |
| Blood pressureb - mmHg [(mean (SD)] | |||||
| Systolic blood pressure | NA | NA | 142 (25) | 139 (22.4) | 141 (23.7) |
| Diastolic blood pressure | NA | NA | 87 (14.4) | 84 (12.8) | 86 (13.7) |
| Number of prescribed medicationsb | |||||
| 1 | NA | NA | 249 (33) | 335 (40) | 584 (36) |
| 2 | NA | NA | 321 (42) | 332 (40) | 653 (41) |
| > = 3 | NA | NA | 193 (25) | 168 (20) | 361 (23) |
| Insulin usec | |||||
| Yes | 204 (100) | 73 (9) | NA | 117 (13) | 394 (21) |
| No | 0 (0) | 705 (91) | NA | 751 (87) | 1456 (79) |
| Characteristics at last visit | |||||
| Number of prescribed medicationsb | |||||
| 1 | NA | NA | 167 (22) | 219 (26) | 386 (24) |
| 2 | NA | NA | 296 (39) | 325 (38) | 621 (38) |
| > = 3 | NA | NA | 300 (39) | 310 (36) | 610 (38) |
| Insulin usec | |||||
| Yes | 204 (100) | 141 (18) | NA | 190 (22) | 535 (29) |
| No | 0 (0) | 639 (82) | NA | 690 (78) | 1329 (71) |
| Follow-up period while in the program - months (median, IQR) | 14 (6–23) | 11 (4–19) | 13 (5–25) | 16 (6–26) | 13 (5–24) |
| Lost to follow-up - n (%) | 18 (9) | 133 (17) | 136 (17) | 139 (16) | 426 (16) |
DM-1 type-1 diabetes, DM-2 type-2 diabetes, HTN hypertension, IQR interquartile range, NA not applicable, SD standard deviation
aCardiovascular co-morbidity is defined as one of the following: ischemic heart disease, heart failure, transient ischemic attack, cerebrovascular accident, or peripheral arterial disease
bCalculated for patients with hypertension; 43 patients (2.6%) had this data missing in their files and were excluded from the calculation
cCalculated for patients with diabetes